前列腺特异性膜抗原PET评分系统与解读框架导航
本文概述了前列腺癌PSMA PET的多种评分系统与解读框架,包括PROMISE v2、PSMA-RADS、PPP标准、RECIP 1.0以及EANM指南等,并讨论了各系统的优势与不足。这些系统旨在标准化PSMA PET的解读与报告,促进影像专业人员、临床医生和患者之间的沟通。
要点
- PROMISE v2整合PRIMARY五分法、分子影像TNM分期和PSMA表达评分。
- PSMA-RADS依据前列腺癌存在可能性对PSMA PET/CT表现进行分类。
- PPP标准关注新病灶及临床或生化进展,RECIP 1.0评估总PSMA阳性肿瘤体积变化。
核心结论
- PSMA PET评分系统与解读框架对优化前列腺癌管理及促进影像专业人员、临床医生和患者之间的沟通具有重要作用,但各系统存在潜在优势与不足。
研究设计与样本
- 本文为综述,检索范围与纳入文献原文未报告。
诊断标准与关键数值
- PROMISE v2分类整合用于评估局部病变的PRIMARY五分法、用于评估病变范围的分子影像TNM分期以及用于评估PSMA靶向放射配体治疗资格的PSMA表达评分。
- PSMA-RADS依据前列腺癌存在可能性对PSMA PET/CT表现进行分类。
- PPP标准关注新病灶及临床或生化进展,RECIP 1.0评估新病灶和总PSMA阳性肿瘤体积的变化。
- EANM E-PSMA指南和EANM-SNMMI程序指南提供标准化报告建议,纳入PROMISE、PSMA-RADS和PPP等现有系统的要素。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Prostate-specific membrane antigen (PSMA) PET is a powerful tool for prostate cancer staging and restaging, providing higher sensitivity and specificity than conventional imaging. The recognition of interpretive pitfalls led to the development of various scoring systems and frameworks, which in turn created challenges for consistent interpretation. The Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) version 2 classification integrates the five-point PRIMARY score for assessing local disease, the molecular imaging TNM stage for disease extent, and the PSMA expression score to assess eligibility for PSMA-targeted radioligand therapy. The PSMA Reporting and Data System (PSMA-RADS) classifies PSMA PET/CT findings on the basis of the likelihood of presence of prostate cancer. For assessing therapy response, PSMA PET Progression (PPP) criteria focus on new lesions and clinical or biochemical progression, whereas Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) assess new lesions and changes in total PSMA-positive total tumor volume. The European Association of Nuclear Medicine (EANM) E-PSMA guideline and EANM-Society of Nuclear Medicine and Molecular Imaging procedure guidelines provide standardized reporting recommendations, incorporating elements from existing systems such as PROMISE, PSMA-RADS, and PPP. Nevertheless, such systems can be essential for optimizing prostate cancer management and facilitating communication among imaging professionals, clinicians, and patients. This article outlines these systems and discusses potential strengths and weaknesses.
引用
- Woo S, Masci B, Rowe SP, et al. Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PET. Radiology. 2025. PMID: 41363980. doi:10.1148/radiol.250701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。